The jumpstart model reduces drug development risk by starting with existing drugs which are then reformulated or repurposed for new or expanded indications. In every case, the parent drug either already belongs to somebody else or has lost patent protection, or soon will, and is therefore freely available for others to exploit. As such, early competition is a significant risk for any jumpstart product. Devising an IP fence high enough to protect a new product could determine a company's success going forward.
by Marc Wortman
In March, a British court struck down GlaxoSmithKline PLC 's composition-of-matter patent for its most important new drug, the...
Join thousands of industry professionals who rely on Scrip for daily insights
Already a subscriber?
Highlights from day one of the BIO convention include advice for firms hoping to go public, a call for companies to push the US Congress on rare disease priority review vouchers, and updates on next-generation gene therapies.
With two deaths in non-ambulatory DMD patients, Sarepta is attempting damage control and will ask the US FDA to advise, setting up a possible confrontation with CBER director Prasad.
Supernus agreed to pay $561m upfront plus a contingent value right that could add $234m to buy Sage, topping a previously rejected offer from Biogen.
First results for a first-in-class mutCALR-targeted therapy in essential thrombocythemia presented at EHA point to a lucrative future for the early-stage product.
In this week's episode: breaking down big pharma’s executive pay; US vaccine panel upheaval; Merck’s RSV approval; MFN and Japan; and the future of Pfizer and Arvinas’s partnership.
UroGen’s Zusduri was approved despite an advisory committee vote recommending against it in May. It is the first approved drug for a type of recurring bladder cancer.
Private Company Edition: Antares’ lead asset will enter the clinic in 2026 after Lilly committed up to $2.5bn for Scorpion’s Phase I/II PI3Kα inhibitor STX-478. Also, Amplify raised $200m for its first biotech VC fund and Mosanna raised an $80m series A round, among other financings.
